Edition: India  
 
> >

Merck to halt study of mild to moderate Alzheimer's drug

Reuters India Tuesday, 14 February 2017
(Reuters) - Merck & Co Inc said it would halt a late-stage trial of its drug in patients with mild to moderate Alzheimer's disease after an external panel pointed to a lack of effectiveness.
0
shares
Share on
Facebook
Share on
Twitter
Post on 
Reddit
Share by
Email
 
Source: Wochit News - < > Embed

News video: Scientists Disappointed After New Alzheimer's Drug Failed

Scientists Disappointed After New Alzheimer's Drug Failed 00:35

Researchers found that the new promising Alzheimer’s drug verubecestat did not work. Dr. Roger Perlmutter, president of Merck Research Laboratories, stated, “While we are disappointed that a benefit was not observed in this study, our work continues [to study the impact of] verubecestat in people...

You Might Like


Other recent news in Health

WHO chief selects Zimbabwe's MUGABE as 'goodwill ambassador'Judge overturns $417M award against JOHNSON & JOHNSON in ovarian cancer case
Motherisk hair test evidence tossed out of Colorado court 2 decades before questions raised in CANADA

Twitter

Environmentally friendly: newsR is hosted on servers powered solely by renewable energy
© 2017 newsR / One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter